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Identification of Peroxiredoxin-1 as a Novel Biomarker of
Abdominal Aortic Aneurysm
Roxana Martinez-Pinna, Priscila Ramos-Mozo, Julio Madrigal-Matute, Luis M. Blanco-Colio,
Juan A. Lopez, Enrique Calvo, Emilio Camafeita, Jes S. Lindholt, Olivier Meilhac, Sandrine Delbosc,
Jean-Baptiste Michel, Melina Vega de Ceniga, Jesus Egido, Jose L. Martin-Ventura
Objective—In the search of novel biomarkers of abdominal aortic aneurysm (AAA) progression, proteins released by
intraluminal thrombus (ILT) were analyzed by a differential proteomic approach.
Methods and Results—Different layers (luminal/abluminal) of the ILT of AAA were incubated, and the proteins released
were analyzed by 2-dimensional difference in-gel electrophoresis. Several differentially expressed proteins involved in
main AAA pathological mechanisms (proteolysis, oxidative stress, and thrombosis) were identified by mass
spectrometry. Among the proteins identified, peroxiredoxin-1 (PRX-1) was more released by the luminal layer
compared with the abluminal layer of the ILT, which was further validated by Western blot, ELISA, and
immunohistochemistry. We demonstrated increased PRX-1 serum levels in AAA patients compared with healthy
subjects and also positive correlation among PRX-1 and AAA diameter, plasmin-antiplasmin, and myeloperoxidase
levels. Finally, a prospective study revealed a positive correlation between PRX-1 serum levels and AAA expansion
rate. Moreover, the combination of PRX-1 and AAA size had significantly additive value in predicting growth.
Conclusion—Several proteins associated with AAA pathogenesis have been identified by a proteomic approach in
ILT-conditioned medium. Among them, PRX-1 serum levels are increased in AAA patients and correlate with AAA size
and growth rate, suggesting the potential use of PRX-1 as a biomarker for AAA evolution. (Arterioscler Thromb Vasc
Biol. 2011;31:935-943.)
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Abdominal aortic aneurysm (AAA) is an important healthproblem, which occurs in up to 9% of adults older than
65 years of age. The incidence of asymptomatic and ruptured
AAA has increased during recent decades, causing 1% to
2% of male deaths in Western countries.1 Because AAAs are
usually asymptomatic before rupture, the present clinical
challenges are to diagnose AAA at an early stage and to
decipher the biological mechanisms leading to progressive
dilatation and finally rupture, to develop new diagnostic and
therapeutic approaches. Identification of biomarkers could
help to target both objectives.
Previous studies have identified AAA biomarkers by
studying the levels of different molecules potentially
related to AAA pathological mechanisms.2,3 A different
noncandidate biomarker strategy using a set of modern
high-throughput technologies, including proteomics, will
offer new opportunities to gain a deeper insight into
disease processes, including their molecular mechanisms,
the risk factors involved, and the analysis of disease
progression.4,5 We have previously reported a differential
proteomic approach to identify new atherothrombosis bio-
markers released by the arterial wall into plasma using
normal and pathological arteries in culture.6,7 The presence
of an intraluminal thrombus (ILT) is a main feature of
AAA, and recent data suggest that the biological activities
of ILT play a major role in AAA development in humans.8
In this study, different layers (luminal/abluminal) from the
ILT of human AAA patients were incubated in protein-free
medium, and the released proteins were analyzed by a
gel-based (2-dimensional difference in-gel electrophoresis
[2D-DIGE]) proteomic approach followed by protein iden-
tification by mass spectrometry (MS). We focused on
peroxiredoxin-1 (PRX-1) in view of its potential role in
modulating oxidative stress and thus validated its differ-
ential expression by Western blot and ELISA in the
conditioned medium. Finally, the suitability of PRX-1 as a
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biomarker of AAA presence and progression was assessed
in sera from 2 different population studies by ELISA.
Materials and Methods
AAA Tissue and Tissue-Conditioned Media
Ten human AAA thrombus samples were collected during surgical
repair and dissected into luminal and abluminal parts (at the
interfaces with circulating blood and with the remaining media,
respectively). AAA samples were obtained from patients undergoing
surgery, enrolled in the RESAA protocol (Reflet sanguin de
l’e´volutivite´ des ane´vrysmes de l’aorte abdominale; Comités Con-
sultatifs de Protection des Personnes dans la Recherche Biomédicale
Paris-Cochin numbers 2095, 1930, and 1931).9 All patients gave
their informed written consent, and the protocol was approved by a
French ethics committee (Comités Consultatifs de Protection des
Personnes dans la Recherche Biomédicale, Cochin Hospital). Lumi-
nal and abluminal layers of AAA thrombus were cut into small
pieces (5 mm3) and separately incubated in RPMI 1640 medium
containing antibiotics and an antimycotic (Gibco) for 24 hours at
37°C (6 mL/g of wet tissue). The conditioned medium (supernatant
containing proteins released by the tissue sample) was obtained after
centrifugation at 3,000g for 10 minutes at 20°C. The protein
concentration of each conditioned medium was measured using the
Bradford assay (Bio-Rad).
Sample Preparation and DIGE Protein Labeling
Supernatants from luminal and abluminal layers of ILT human
samples from 4 individual patients were isolated, and the proteins
were precipitated using the 2D clean-up kit (GE Healthcare) and
resuspended in 30 mmol/L Tris-HCl, pH 8.5, 7 mol/L urea, 2 mol/L
thiourea, and 40 g/L CHAPS. Protein concentration was measured by
RC-DC protein assay kit (Bio-Rad).
The comparison between the proteins released by luminal and
abluminal layers was performed by 2D-DIGE analyses across 4 gels,
using the same pooled-sample internal standard, the equimolecular
mixture of all the samples, in all gels. The samples were labeled
according to manufacturer’s instructions for minimal labeling, using
400 pmol of dye reagent for 50 g of protein extract. Individual
samples were labeled with Cy3 or Cy5 dyes using dye switching, and
the internal standard was always Cy2 labeled. The labeling reaction
was performed on ice for 30 minutes in darkness and quenched by 1
L of lysine (10 mmol/L) for 10 minutes.
2D Electrophoresis and Image Acquisition
The 4-paired samples of Cy3- and Cy5-labeled proteins were mixed
with 50 g of Cy2-labeled internal standard. The mixtures were
diluted in rehydration buffer (7 mol/L urea, 2 mol/L thiourea, 40 g/L
CHAPS, 0.8% IPG buffer 3-11NL, and bromphenol blue) containing
50 mmol/L immobilized pH gradient and resolved on 24-cm pH
3–11 nonlinear gradient IPG strips (GE Healthcare). The samples
were applied by cup loading to the previously rehydrated IPG Strips
with 450 L of the aforementioned rehydration buffer containing
97 mmol/L DeStreak (GE Healthcare).
The isoelectric focusing was carried out in an IPGphor II isoelec-
tric focusing system (GE Healthcare) until a total of 42 kVh was
reached. After isoelectric focusing, strips were equilibrated in buffer
containing 6 mol/L urea, 400 mmol/L glycerol, 7 mmol/L SDS, and
bromphenol blue, for 15 minutes with addition of 6.5 mmol/L
dithiothreitol, and then without dithiothreitol but with the same
buffer supplemented with 21.6 mmol/L iodoacetamide for an addi-
tional 15 minutes. SDS-PAGE was carried out on 12% polyacryl-
amide gels at 2 W/gel.
The differentially labeled coresolved proteins in each gel were
acquired with a Typhoon 9400 laser scanner (GE Healthcare), and
Cy2-, Cy3-, and Cy5-labeled images of each gel were acquired at
excitation/emission wavelength values of 488/520, 523/580, and
633/670 nm, respectively. Finally, gels were fixed in 12% methanol
and 7% acetic acid and silver stained using the Plus One silver
staining kit (GE Healthcare).
DIGE Data Analysis
The images were analyzed using the DeCyder version 6.5 software
(GE Healthcare) for spot detection and quantification and intergel
matching and statistics. DeCyder calculates the average abundance
for each spot among the 4 gels under study. Statistical significance
was assessed for each change in abundance using the paired Student
t test analysis. We considered spots present in all of the 12 images
(Cy2-, Cy3-, and Cy5-labeled images of each gel) with statistical
significance at 95% confidence level for standardized average spot
volume ratios greater than 1.5.
Protein Identification by Matrix-Assisted Laser
Desorption Ionization-MS
Differentially expressed spots were selected from silver-stained gels
for gel excision, automated digestion,10 and analysis in an Ultraflex
matrix-assisted laser desorption ionization (MALDI) time-of-flight/
time-of-flight mass spectrometer (Bruker Daltonik) to obtain the
corresponding MALDI-MS and MALDI-MS/MS spectra as de-
scribed.11,12 These MS and MS/MS combined data were used to
search a nonredundant protein database (NCBInr; 107 entries;
National Center for Biotechnology Information, Bethesda, MD)
using the Mascot software (Matrix Science).13 Detailed information
is included the Supplemental Methods, available online at
http://atvb.ahajournals.org.
Western Blot
Equal amounts (50 g of protein) of conditioned medium were
loaded onto 12.5% polyacrylamide gels, electrophoresed, and trans-
ferred to nitrocellulose membranes. Then they were blocked with 7%
milk powder in TBS-T for 1 hour and incubated overnight at 4°C at
1:500 with anti-peroxiredoxin antibody (Santa Cruz Biotechnology,
goat polyclonal sc-23969). Then, the membranes were washed with
TBS-T and incubated with anti-goat antibody (1:2000) for 1 hour at
room temperature. After 4 washes, the signal was detected using the
ECL chemiluminiscence kit (GE Healthcare).
ELISA
The soluble concentration of PRX-1 in both conditioned media and
serum was quantified with a commercial kit following the manufac-
turer’s instructions (AbFrontier). The interassay and intraassay
variability values were 9% and 6%, respectively.
Immunohistochemistry
AAA thrombus samples were fixed in 3.7% paraformaldehyde and
embedded in paraffin. Immunohistochemistry was performed on
5-m sections, using rabbit anti-peroxiredoxin 1 (ab-15571) at 1:100
overnight at 4°C as the primary antibody. The peroxidase LSAB
system horseradish peroxidase kit (Dako), followed by Histogreen
peroxidase substrate (AbCys SA), was used for detection. Sections
were then counterstained with Nuclear Fast Red for 5 minutes at
room temperature before being mounted using Eukitt medium.
Control irrelevant rabbit immunoglobulins (Dako) were applied at
the same concentrations as primary antibodies to assess
nonspecific staining.
Red Blood Cell In Vitro Experiments
Blood was collected in EDTA-tubes from 6 healthy volunteers. The
blood sample was centrifuged at 2500 rpm for 15 minutes to
eliminate plasma, and then blood cells were diluted 1:1 in PBS
(154 mmol/L NaCl, 10 mmol/L phosphate buffer, pH 7.4) and were
separated by centrifugation in Ficoll-Paque (GE Healthcare). Finally,
red blood cells (RBCs) and leukocytes were separated by 6% dextran
sedimentation of the pellet. Erythrocytes were incubated with lipo-
polysaccharide (0.1 and 1 ng/mL) and H2O2 (5 and 500 mol/L) for
30 minutes. The lysis of RBCs was achieved by hypotonic shock,
using repetitive washes with distilled water, and finally by adding
NaCl (3.5%). Membrane fractions were collected after centrifugation
at 12 000 rpm for 10 minutes.
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Hydrogen Peroxide Quantification
Quantitative determination of hydrogen peroxide was performed
with a commercial colorimetric kit (907-015, Assay Design) follow-
ing the manufacturer’s instructions.
AAA Patient Sera
Spanish Study
The study was approved by the Spanish center’s research and ethics
committees, and informed consent from the patients and the controls
for their inclusion in the study was obtained. Eighty-three consecu-
tive patients with an asymptomatic infrarenal AAA were recruited,
and for each, the AAA size at the time of blood sample collection
was registered (Supplemental Table I). We excluded patients with
symptomatic or inflammatory AAA, multiple synchronic aneurysms
(thoracic, femoral, popliteal), and AAA with a location other than
infrarenal. We also excluded patients with active inflammatory or
acute infectious processes, surgical procedures or major trauma in
the previous 60 days, and chronic antiinflammatory or immunosu-
pressive medication.
Thirty-three controls were recruited from a screening program,
which is currently being performed among the population in the area
under our care.14 They were randomly selected from the screened
individuals with nondilated (30 mm, confirmed with abdominal
ultrasound) infrarenal aortas. Neither patients nor controls showed
any significant differences in age, sex, or cardiovascular risk factors.
Viborg Study
In 1994, half (4404) of all 65 to 73 year-old males in Viborg County,
Denmark, were invited to B-mode-ultrasonographic screening for
AAA at their regional hospital. The trial was approved by the
respective local scientific ethics committees and reported to the
Danish Central Control of Registers.
An AAA was defined as an infrarenal aortic diameter of 30 mm or
more, and AAAs 50 mm were referred for surgery. AAAs of 30 to
49 mm were offered yearly follow-up examinations to check for any
expansion.15 Two observers were used, and the arithmetic interob-
server variation (2 SD) was 1.4 mm.16
The serum samples were left for coagulation at room temperature
for 45 minutes before centrifugation. A random sample of 80 cases
was used in this study of peroxiredoxin. Follow-up was truncated
after 10 years. Sixteen men were referred to planned AAA repair
because of expansion (Supplemental Table II). The expansion rate
was calculated as the change in the anteriorposterior diameter during
the whole observation period, transformed to annual units. The trial
was approved by the respective local scientific ethics committees and
reported to the Danish Central Control of Registers.
Statistics
ELISA and Western blot results are expressed as meanSEM.
The Wilcoxon paired test was used to analyze differences in
PRX-1 levels between luminal and abluminal supernatants of the
same samples. The analysis of small and large AAA and control
groups was performed with nonparametric tests (Mann-Whitney
U tests). Pearson correlation analysis was used to examine the
univariate correlation between PRX-1 and AAA expansion rate,
and it was adjusted for current smoking, body mass index,
previous cardiovascular events, use of glucocorticoids, low-dose
aspirin, -blockers, angiotensin coverting enzyme inhibitors, and
ankle brachial blood pressure index. The receiving-operating
characteristic (ROC) curve analysis was performed to test the
predictive clinical value of PRX-1 and initial AAA size, univar-
iately and combined in a multivariate linear regression model
concerning prediction of cases expanding more than 1.68 mm/
year (mean annual growth). For the analysis of the ROC curve,
the null hypothesis was that the test had a performance similar to
the diagonal line, ie, the area under the curve was 0.5. If the
lowest 95% confidence limit for the area under the curve was
more than 0.5, a significant predictive test was said to be present.
Results
DIGE Analysis of ILT Supernatants
Because ILT is involved in AAA evolution and ILT
material can be sampled during surgery, it represents a
highly relevant model for the study of biological events
participating in human AAA. We hypothesized that the
proteins differentially released by the biologically active
luminal part of the ILT versus the abluminal layer may
reflect ILT activity. Proteins released from these different
layers (luminal/abluminal) of the ILT of AAA were
analyzed by a noncandidate based proteomic strategy using
2D-DIGE (Figure 1). DeCyder analysis revealed 42 differ-
entially expressed spots, and after silver staining of the
gels, only visible spots were excised, digested with trypsin,
and subjected to MS-based protein identification. Thirty-
two proteins out of the 42 spots released differently by the
luminal layer compared with the abluminal layer were
finally identified by MS (Table and Supplemental Figure
I); these proteins are involved in different AAA patholog-
ical mechanisms, such as redox balance (eg, peroxire-
doxin), inflammatory processes (eg, complement compo-
Figure 1. DIGE of AAA-
conditioned media. Luminal
and abluminal layers from ILT
of 4 AAA patients were incu-
bated in protein-free medium.
Secreted proteins were labeled
with the corresponding CyDye
reagents, mixed, resolved on 4
independent DIGE gels, and
imaged (red, Cy3; green, Cy5;
blue, Cy2) and analyzed with
DeCyder software. A, A repre-
sentative gel image from the
3-plex DIGE experiment is
shown. Proteins were resolved
in the 3 to 11 (nonlinear) pH
range in the first dimension and
on 12% polyacrylamide gels in
the second dimension. B,
Spots showing statistically
significant regulation between the 2 conditions were excised from silver-stained gels and identified by MALDI-MS. Identified spots are
numbered as listed in the Table.
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nents), extracellular matrix remodeling (thrombospondin),
hemostasis (eg, fibrinogen), or heme-related proteins (eg,
hemopexin).
PRX-1 Is Mainly Localized and Released by the
Luminal Part of AAA Thrombus
Among the differential proteins identified by 2D-DIGE and
MS that were found to be altered in the 4 patients and not
previously related to AAA, we focused on PRX-1 because
regulation of oxidative stress is of major importance in AAA
pathophysiology. We validated the levels of PRX-1 in the
conditioned media from the same samples used in the DIGE
experiment (n4) and from an additional group of human
AAA samples (n6). PRX-1 release was increased in the
luminal layer of the ILT of AAA compared with the ablumi-
nal layer, as assessed by ELISA (3210 versus 102 ng/mL,
Table. Proteins Differentially Released From Different Layer Regions (Luminal/Abluminal) of the ILT of Human AAA as Revealed by
2D-DIGE and Identified by MALDI-MS
DeCyder*
Protein Description†
Accession
Code†
Mascot‡ Theoretical
Molecular
Mass
(kDa)/pI
Matched
Peptides§
Unmatched
Peptides§
Coverage
(%)§Spot
Average
Ratio t Test
Total
Score Expected
Ion
Score
1 2.57 3.81102 Complement component C3 gi 78101268 194 3.101013 NA 114.2/5.55 16 4 18
2 7.35 4.53102 Complement component C3 gi 78101268 230 7.801017 NA 114.2/5.55 20 3 23
3 2.03 6.97103 Complement component C4A gi 179674 133 3.90107 NA 189.1/6.7 11 1 7
4 2.05 4.31102 Complement component C4A gi 179674 444 5.301040 263 194.3/6.65 17 4 11
5 1.74 4.68102 Transketolase gi 388891 300 7.701024 83 685.3/7.89 13 1 28
6 1.96 2.82104 Complement component C3 gi 78101267 642 4.801058 341 71.3/6.82 18 2 43
7 1.85 2.5102 Transketolase gi 58176651 209 9.701015 98 56.8/7.16 8 3 22
8 1.84 2.48102 Phosphoglucomutase 1 gi 21361621 279 9.701022 71 61.7/6.3 13 3 29
9 1.67 1.85102 Antithrombin III gi 999513 474 3.101041 321 49.4/5.95 13 3 39
IGHA1 protein gi 16741036 272 4.801021 109 54.3/8.07 10 3 26
10 1.65 8.42103 Prolyl 4-hydroxylase gi 20070125 113 6.60107 77 57.5/4.76 2 0 6
11 1.58 4.62102 Dihydropyrimidinase-like 2 gi 4503377 208 1.201014 69 62.7/5.95 9 3 20
12 1.52 3.67102 Tubulin--2c gi 14124960 148 2.101010 53 26/4.95 5 1 17
13 1.97 2.38102 Hemopexin gi 386789 152 8.301011 66 52.2/6.57 5 1 16
14 1.81 1.27102 Enolase 1 gi 203282367 403 3.901034 213 47.4/6.99 13 4 41
15 2.14 4.93103 Trypsin-like serine protease gi 47124562 148 2.101010 77 31.7/8.48 4 1 14
16 1.55 6.04104 3-Immunoglobulin gi 1628395 99 2.70105 52 38.7/8.37 3 2 9
17 1.65 4.15102 Fibrinogen- gi 223170 88 3.20104 NA 33.6/5.98 5 2 22
18 3.88 3.03102 Fibrinogen fragment D gi 2781208 545 4.201050 165 38.1/5.84 22 3 62
19 4.59 3.97102 Macrophage capping protein gi 21730367 136 3.30109 85 38.8/5.32 3 2 12
20 2.08 3.38102 Ig1 gi 226787 128 1.20106 47 25.6/7 4 1 21
21 2.14 8.32103 Ig1 gi 226787 148 1.20108 47 25.6/7 5 1 26
22 1.74 2.69102 Ig1 gi 226787 129 1.70108 48 25.6/7 4 1 21
23 2.13 1.64102 Ig1 gi 5031410 123 6.60108 59 25.4/6.95 3 0 15
24 2.87 2.1102
Glyceraldehyde 3-phosphate
dehydrogenase gi 7669492 199 1.701015 98 36.2/8.57 5 0 22
25 2.67 4.94102 Complement component C4A gi 443671 430 1.301038 315 195.2/6.79 17 5 8
26 1.91 3.62102
Phosphatidylinositol transfer
protein gi 5453908 129 1.70108 59 32/6.11 4 0 13
27 1.58 3.71102 Thrombospondin gi 553801 216 3.301017 138 42.2/6.6 5 0 14
28 19.01 8.49103 Fibrinogen -chain gi 76779196 279 1.701023 100 29.2/9.51 12 5 34
29 7.72 1.84102 Fibrinogen -chain gi 76779196 718 2.101067 399 29.2/9.51 21 6 58
30 1.78 1.22102 Peroxiredoxin 1 gi 55959888 134 3.10107 63 10.7/8.79 3 0 34
31 10.61 3.69102 Transgelin gi 48255905 184 5.301014 74 22.7/8.87 6 2 34
32 3.15 3.23102 Haptoglobin- gi 296653 237 2.601019 139 42.1/6.25 7 3 20
*Protein spot number according to Figure 1 and average volume ratio (luminal/abluminal) as quantified by DeCyder.
†Protein ID and accession number according to the National Center for Biotechnology Information database.
‡Mascot score, expected value, and ion score. NA indicates not applicable. Supplemental Figure I provides annotated MALDI-MS spectra. Ion score applies to
peptide MS/MS fragmentation spectra.
§Number of peptides matching and not matching the protein sequence and protein sequence coverage.
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P0.05) and Western blot (Figure 2). Immunodetection of
PRX-1 in AAA thrombus (Figure 2D) showed a strong
staining in the luminal layer mainly associated with RBCs
and polymorphonuclear neutrophils.17 Both cellular and dif-
fuse staining was observed, which suggests a potential release
of PRX-1 in the extracellular compartment. On the contrary,
the abluminal layer exhibited a faint staining, in accordance
with results obtained by 2D electrophoresis, Western blot,
and ELISA.
PRX-1 Is Induced and Released by Oxidative
Stress in RBCs
Because the main function of PRX-1 is the inactivation of
hydrogen peroxide (H2O2), we analyzed H2O2 levels in AAA
thrombus-conditioned media. Interestingly, H2O2 levels were
also increased in the luminal layer versus the abluminal layer
(17.25.4 versus 6.41.4 mol/L, P0.05). In addition, in
vitro experiments with isolated RBCs stimulated with H2O2
(and lipopolysaccharide) were performed. We have shown
that H2O2 and lipopolysaccharide induced PRX-1 transloca-
tion to the membrane and final release to the conditioned
medium (Figure 3). These results suggest that PRX-1 is
released as a response to prooxidant molecules present in the
thrombus.
Increased PRX-1 Levels in Serum of AAA Patients
This ex vivo approach offers the advantage of identifying
proteins potentially released into the bloodstream that could
serve as circulating biomarkers for AAA. We measured
circulating PRX-1 levels in the serum of patients and controls
by ELISA. Results showed that PRX-1 levels were signifi-
cantly increased in patients with AAA relative to control
subjects (14.93.5 versus 80.6 ng/mL, P0.001, Figure
4A). Because AAA diameter is a surrogate marker of the
growth rate, we studied the correlation between circulating
PRX-1 levels and AAA diameter. Interestingly, a significant
positive correlation between PRX-1 levels and AAA diameter
was found (r0.6, P0.001, Figure 4B).
Plasmin-antiplasmin (PAP) complexes and myeloperoxi-
dase (MPO) levels are increased in patients with AAA.18,19
We confirmed these data in our patient population (data not
shown). In addition, we have previously shown that both PAP
and MPO levels are increased in the luminal part of the
thrombus.18,19 Interestingly, PRX-1 positively correlated with
Figure 2. PRX-1 is expressed and
released by the luminal part of AAA throm-
bus. A, Average spot volumes corre-
sponding to luminal (L) (n4) and ablumi-
nal (A) (n4) samples are shown from the
DeCyder software (*average ratio1.78;
P0.05). B, Quantification of PRX-1 levels
by ELISA measured in L and A layer
supernatants (n10, *P0.001). C, Repre-
sentative Western blot from L and A layer
supernatants (n10, *P0.001). D, Immu-
nodetection of PRX-1 in AAA thrombus
(magnification, 10). Inset 1 (magnifica-
tion, 20) shows erythrocyte accumulation
with leukocyte (nucleated cells) in the lumi-
nal part of the thrombus. Inset 2 (magnifi-
cation, 20) shows erythrocytes and poly-
nuclear cells positive for PRX-1 at the
interface between the luminal an interme-
diary layers of the thrombus. Positivity is
shown in green and nuclei in red. A.U.
indicates arbitrary units.
Figure 3. Western blot analysis of PRX-1 in RBCs. Representa-
tive Western blots were performed in RBCs isolated from
healthy controls and stimulated with lipopolysaccharide (LPS)
and H2O2 for 30 minutes at different concentrations. A, Total cell
lysates. B, Supernatant obtained from cell culture. C, Membrane
fractions.
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both biomarkers of AAA in our patient population (PAP,
r0.4; MPO, r0.55; P0.05 for both; Figure 4C and 4D).
PRX-1 Circulating Levels Correlate With
AAA Growth
To further extend the results obtained, we measured PRX-1
serum levels in a second cohort of 80 patients from the
Viborg study, with a 5-year follow-up, allowing us to test the
relevance of PRX-1 as a marker of AAA progression. Similar
levels of circulating PRX-1 in small AAA patients (AAA size
3 to 5–5.5 cm) were obtained in both the Viborg and Spanish
studies (Viborg10.43.7 ng/mL versus small AAA Span-
ish8.32.8 ng/mL). Interestingly, the correlation coeffi-
cient between PRX-1 levels and AAA growth rate was 0.3
(P0.01, Figure 5A), persisting after adjustment for current
smoking, body mass index, previous cardiovascular events,
use of glucocorticoids, low-dose aspirin, -blockers, angio-
tensin coverting enzyme inhibitors, and ankle brachial blood
pressure index (Supplemental Table III). ROC curve analyses
showed that PRX-1 levels were equally valid predictors of
Figure 4. PRX-1 levels in AAA.
A, Serum PRX-1 levels were
measured from 33 control sub-
jects and 83 patients with AAA
(*P0.001). B, PRX-1 levels
correlate with AAA diameter
(0.6; P0.001, n83). C
and D, A positive correlation
was observed between PRX-1
and PAP levels (0.4,
P0.01, n83 patients) (D)
and between PRX-1 and MPO
levels (0.5, P0.01, n83
patients) (D).
Figure 5. PRX-1 and AAA growth in the Viborg cohort. A, PRX-1 levels were measured from an additional group of serum samples
(Viborg cohort). PRX-1 correlates with AAA growth (0.3; P0.05, n80). B, ROC curve for predicting AAA expansion concerning
PRX-1 levels and AAA size.
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annual expansion rate as initial AAA size exceeding the mean
annual growth, with optimal cutoff points with a sensitivity
and specificity of 63% and 64%, respectively, for both
(Figure 5B). By combining these 2 predictors (PRX-1 and
AAA-size) by linear regression to predict annual expansion
rate, the optimal validity increased by almost 10% to 72%
sensitivity and 71% specificity. Moreover, comparison of the
C-statistics showed that the 3 ROC curves differed signifi-
cantly (2 test9.11, P0.01). Consequently, the combina-
tion of PRX-1 and size has significantly additive value in
predicting growth compared with size alone.
Discussion
Vascular diseases are currently among the most common
pathologies, and despite outstanding scientific advances in
recent years, the number of effective therapies and useful
biomarkers is still very limited, although there is a contin-
uous increase in costs associated with these diseases.
Although several potential biomarkers of AAA have been
proposed,2,3 it is essential to discover new biomarkers for
early disease detection and risk stratification, which could
predict clinical outcome. Moreover, identification of novel
biomarkers could help decipher the biological mechanisms
leading to progressive dilatation and finally rupture to
develop new therapeutic approaches. Our study was per-
formed on the thrombus conditioned medium as a potential
source of biomarkers of AAA by a gel-based proteomic
approach using DIGE platform. Among the proteins iden-
tified by MS, both novel and previously known protein
biomarkers for AAA have been unveiled that are associ-
ated with some major AAA pathological processes, such as
thrombosis and oxidative stress.
The formation of a luminal thrombus may be considered
a compensatory mechanism in response to flow perturba-
tions associated with AAA dilatation. The mural thrombus
is continuously self-forming at its luminal pole and sub-
jected to proteolysis at the interface with the residual
media. Previous studies have shown that thrombus forma-
tion and accumulation of leukocytes may have an impact
on the structural integrity and stability of the vessel wall
and thereby increase the risk of aneurysm rupture.20
Proteins associated with thrombosis have been the bio-
markers most commonly assessed in AAA. In this respect,
levels of PAP complexes and D-dimers are elevated in
AAA patients and correlate with disease progression.2,3
Similarly, elevated plasma fibrinogen concentrations pre-
dict a greater risk of thrombosis. Interestingly, fibrinogen
levels are increased in AAA patients compared with
controls, and positive correlations of AAA size, ILT, and
fibrinogen concentration are observed.21 In the present
work, among known biomarkers identified, we have shown
that fibrinogen/fibrin fragments are abundantly released by
the luminal part of the thrombus, in agreement with
previous results of our group showing activation of the
fibrinolytic system.19
Oxidative stress plays a key role in AAA pathophysiology.22
Although previous studies have mainly addressed the role of
oxidative stress in AAA wall, the presence of a mural
hemothrombus can also contribute to this process. The
trapping of RBCs within ILT may lead to hemolysis and
subsequent release of the prooxidant hemoglobin that, when
oxidized, transfers heme to endothelium and lipoproteins,
thereby enhancing susceptibility to oxidant-mediated injury.
Heme potentiates cell cytotoxicity mediated by leukocytes
and other sources of reactive oxygen species.23 Plasmatic
hemopexin, haptoglobin, and albumin limit the hemoampli-
fied oxidative damage to the vasculature. In the present work,
a decrease in hemopexin and haptoglobin levels was observed
in the luminal part of the thrombus, which could favor the
prooxidant actions of hemoglobin.
However, oxidative stress is the result of imbalance be-
tween prooxidant and antioxidant molecules. In relation to
antioxidant enzymes, superoxide dismutase, glutathione per-
oxidase, and thioredoxin expression levels are increased in
AAA tissue.24,25 Thioredoxin, thioredoxin reductase, and
NADPH together constitute a ubiquitous system that regu-
lates cellular redox status. PRX-1 can interact and modulate
NADPH activity by inactivating H2O2.26 In this respect, we
observed that H2O2 levels were increased in the luminal layer
versus the abluminal layer, similarly to the tendency observed
for PRX-1. In addition, we have shown that H2O2 induced
PRX-1 translocation to the membrane and final release to the
conditioned medium in isolated RBCs. These results suggest
that PRX-1 is released as a response to the prooxidant
environment present in the ILT.
We hypothesized that the blood compartment could
reflect what was observed in the arterial conditioned
medium and thus that proteins potentially released into the
circulation could serve as biomarkers for the pathology.
We show here for the first time that PRX-1 levels are
significantly increased in the serum of patients with AAA
in relation to controls. Because AAA diameter is a surro-
gate marker of AAA growth rate and is the clinical
parameter used in the management of AAA patients, we
studied its potential correlation with PRX-1. We have
observed that PRX-1 levels and AAA diameter show a
significant positive correlation. Furthermore, a positive
correlation among circulating PRX-1, PAP, and MPO
levels has been shown, supporting the importance of ILT
activities in AAA pathophysiology. Finally, PRX-1 also
correlated with AAA growth in a second population with
follow-up. Interestingly, by combining both AAA size
with PRX-1 levels by linear regression to predict annual
expansion rate above the interobserver variation of the
measurements,16 the optimal validity increased almost by
10% up to 72% sensitivity and 71% specificity. The fact
that PRX-1 correlates significantly with both AAA size
and AAA growth rate in different populations (Spanish and
Viborg studies), together with the observed comparable
circulating levels in small AAA in the 2 populations,
suggests the potential use of PRX-1 as a biomarker for
AAA evolution.
On the other hand, despite the fact that PRX-1 levels
could be increased in response to the oxidative stress
present in AAA, the functional consequences of PRX-1
upregulation are not completely understood. In mammalian
cells, high levels of peroxiredoxins are produced, which
may account for 0.1% to 0.8% of soluble protein.27 PRX-1
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is overexpressed in response to oxidative stress and has
recently been involved in other mechanisms, such as shear
stress.28 Several studies support an antioxidant and anti-
apoptotic role for PRX-1 upregulation. PRX-1 was initially
described mainly as an antioxidant protein because of its
ability to inactivate H2O2, ONOO2, and other hydroper-
oxides. However, other cellular roles have been recently
proposed for PRX-1, including the modulation of cyto-
kine-induced H2O2 levels, which have been shown to
mediate the signaling cascade that leads to cell prolifera-
tion, differentiation, and apoptosis,29 and proinflammatory
actions.30 In this respect, PRX-1 has been shown to interact
with other proteins and ligands, including hemo and
macrophage migration inhibitor factor (MIF).27,31 MIF is
upregulated in AAA32 and MIF serum levels have been
correlated with annual AAA expansion rate and initial
AAA size.33 Interestingly, we have observed a significant
strong positive correlation between PRX-1 and MIF in the
Viborg sample cohort (not shown). MIF, by modulating the
redox status of PRX-1, has been suggested to modulate
signaling pathways and glucocorticoid sensitivity.31 Like-
wise, we have observed a positive correlation between
PRX-1 levels and glucocorticoid treatment.
In the present study, several proteins associated with key
mechanisms involved in AAA pathogenesis have been iden-
tified by a non-hypothesis-driven proteomic approach.
Among them, increased PRX-1 levels have been observed
both in conditioned media and in serum from AAA patients.
PRX-1 serum levels are associated with AAA size and
growth rate, suggesting its possible use as a biomarker for
AAA evolution. Additional prospective studies are needed to
confirm these results. These results support a main patholog-
ical role of oxidative stress in AAA,22 as well as the potential
usefulness of therapies aimed at enhancing antioxidant path-
ways to prevent AAA progression.34
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTARY METHODS 
In-gel trypsin digestion 
Protein spots from silver-stained gels were visually matched against DIGE images, manually 
excised from gels, and transferred to pierced V-bottom 96-well polypropylene microplates 
(Bruker Daltonik, Bremen, Germany) loaded with ultrapure water. Samples were digested 
automatically using a Proteineer DP protein digestion station (Bruker Daltonik) according to 
the protocol of Schevchenko et al. (1) with minor variations: gel plugs were submitted to 
reduction with 10 mmol/l DTT (GE Healthcare, Uppsala, Sweden) in 50 mmol/lammonium 
bicarbonate (99.5% purity; Sigma Chemical, St. Louis, MO, USA) and alkylation with 55 
mmol/l iodoacetamide (Sigma Chemical) in 50 mmol/l ammonium bicarbonate. Gel pieces 
were then rinsed with 50 mmol/l ammonium bicarbonate and acetonitrile (gradient grade; 
Merck, Darmstadt, Germany) and dried under a nitrogen stream. Modified porcine trypsin 
(sequencing grade; Promega, Madison, WI, USA) at a final concentration of 7.5 ng/µl in 50 
mmol/l ammonium bicarbonate was added to the dry gel pieces, and digestion proceeded at 
37ºC for 10 h. The resulting digestion solutions were transferred by centrifugation to V-
bottom 96-well polypropylene microplates (Greiner Bio-One, Frickenhausen, Germany), 
vacuum-dried and kept at 4ºC for later MS analysis.  
MALDI Mass spectrometry 
Dried samples were redissolved in 0.2 g/l α-cyano-4-hydroxycinnamic acid (Bruker 
Daltonik) in 50% aqueous acetonitrile and 0.2% trifluoroacetic acid (99.5% purity; Sigma 
Chemical). This solution was deposited onto a 600 µm AnchorChip prestructured MALDI 
probe (Bruker Daltonik) (2) and allowed to dry at room temperature. Samples were 
automatically analyzed in an Ultraflex MALDI-TOF/TOF mass spectrometer (Bruker 
Daltonik) (3) with an automated analysis loop controlled by the flexControl 2.2 software 
(Bruker Daltonik). In a first step, MALDI-MS spectra were acquired by averaging 400 
individual spectra in the positive ion reflector mode at 50 Hz laser frequency in a mass range 
from 800 to 3500 Da. Internal calibration of MALDI-MS mass spectra was performed using 
two trypsin autolysis ions with m/z = 842.510 and m/z = 2211.105. In a second step, 
precursor ions showing in the MALDI-MS mass spectrum were subject to fragment ion 
analysis in the tandem (MS/MS) mode to average 1200 spectra. For MALDI-MS/MS, 
calibrations were performed with fragment ion spectra obtained for the proton adducts of a 
peptide mixture covering the 800-3200 m/z region. Automated analysis of mass data was 
performed using the flexAnalysis 2.2 software (Bruker Daltonik). No smoothing or any 
further spectral processing was applied. MALDI-MS and MS/MS spectra were manually 
inspected in detail and reacquired, recalibrated and/or relabeled using the aforementioned 
programs and homemade software when necessary.  
MALDI-MS Database searching 
MALDI-MS and MS/MS data were combined through the BioTools 3.0 program (Bruker 
Daltonik) to search a nonredundant protein database (NCBInr 20091015, ~ 107 entries, 
National Center for Biotechnology Information, Bethesda US), using the Mascot software 
v2.2 (Matrix Science, London, UK; http://www.matrixscience.com) (4). Other relevant 
search parameters were set as follows: enzyme, trypsin; fixed modifications, 
carbamidomethyl (C); allow up to 1 missed cleavage; peptide tolerance ±20 ppm; MS/MS 
tolerance ±0.5 Da. Protein scores greater than 82 were considered significant (p<0.05). 
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TABLE I (online). Characteristics of the patients included in the Spanish Cohort Study 
	  
	  
	  	  	   	   	   	   	   	   	   	   	  
	   N	   %	  Previous	  hypertension	   50	   55	  Previous	  dyslipemic	  	   56	   65	  Previous	  diabetes	   11	   14	  Previous	  cardiovascular	  diseases	   32	   36	  Past/present	  smokers	   41	   46	  Use	  of	  aspirin	   33	   37	  Use	  of	  statin	   50	   55	  Use	  of	  Ace	  inhibitors	   37	   42	  
 
	   
TABLE II (online). Characteristics and events of the included men from The Viborg Cohort 
Study 
	  
	  
	  
	  
	   N	   %	  Previous	  hypertension*	   10	   12.8	  Previous	  cerebral	  ischaemic	  attack*	   4	   5.1	  Previous	  angina	  pectoris*	   12	   15.4	  Previous	  acute	  myocardial	  infaction*	   20	   25.6	  Previous	  lower	  limb	  ischaemia*	   5	   6.4	  Current	  smokers	   45	   57.7	  Use	  of	  low	  dose	  aspirin	   37	   47.4	  Use	  of	  statin	   0	   0.0	  Use	  of	  Betablockers	   15	   19.2	  Use	  of	  Ace	  inhibitors	   10	   12.8	  Planned	  repair	  due	  to	  progression	   16	   20.5	  Dead	   37	   47.4	  
	   N	   Mean	   SD	  Age	  at	  inclusion	   78	   68.1	   2.9	  Systolic	  brachial	  blood	  pressure	  (mmHg)	   78	   157.8	   21.6	  Diastolic	  brachial	  blood	  pressure	  (mmHg)	   78	   92.6	   13.2	  Ankle	  brachial	  blood	  pressure	  index	   78	   0.99	   0.24	  Body	  Mass	  Index	  (kg/m2)	   78	   27.0	   3.9	  Initial	  AAA-­‐size	  (mm)	   78	   33.4	   4.0	  Annual	  aneurismal	  growth	  rate	  (mm/year)	   78	   2.22	   1.56	  
 
*  Identified by national-wide registry of hospital-diagnoses at discharge from hospital 
Table III (online). Multivariant analysis performed on Viborg cohort study 	  	  
  Coefficients(a)       
Unstandardized 
Coefficients 
Standardized 
Coefficients Model 
B Std. Error Beta 
t Sig. 
(Constant) -4,997 2,096   -2,384 0,02 
Peroxiredoxin-1 0,106 0,048 0,251 2,21 0,031 
Initial AAA-size 0,142 0,045 0,354 3,147 0,002 
Current smoking 0,936 0,378 0,287 2,48 0,016 
Use of glucocorticoids -0,344 0,58 -0,069 -0,593 0,555 
Body mass index 0,001 0,047 0,001 0,013 0,99 
Coexisting cardiovascular 
disease 0,348 0,409 0,107 0,85 0,398 
Ankle brachial 
bloodpressure index 0,783 0,748 0,117 1,047 0,299 
Use of β-blocker -0,167 0,516 -0,041 -0,323 0,747 
Use of ACE-inhibitor 0,468 0,56 0,098 0,836 0,406 
Use of low-dose aspirin -0,048 0,374 -0,015 -0,128 0,899 	  
a	  Dependent	  Variable:	  Mean	  annual	  aneurismal	  expansion	  rate	  (mm/year)	  	  
  
SUPPLEMENTARY FIGURE. 
Supplementary Figure I. MALDI-MS spectra corresponding to proteins identified without 
MS2 data. 
 	  
